Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARCT 032

Next Previous
X
Search
Drug Profile

ARCT 032

Alternative Names: ARCT-032; ARTC032; LUNAR CF - Arcturus Theraepeutics; LUNAR-CF; mRNA CFTR therapeutic - Arcturus Therapeutics

Latest Information Update: 05 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcturus Therapeutics
  • Developer Arcturus Therapeutics; Cystic Fibrosis Foundation Therapeutics
  • Class Antifibrotics; RNA
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 03 Sep 2024 Arcturus Therapeutics receives IND clearance from the FDA for ARCT 032 in Cystic fibrosis
  • 01 Jul 2024 Arcturus Therapeutics plans to submit an IND application, to initiate a phase II trial for Cystic fibrosis by September 2024
  • 10 Jun 2024 Efficacy and adverse events data from a phase I trial in Cystic fibrosis released by Arcturus Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top